{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:53:47Z","timestamp":1793246027867,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.imlet.2021.03.011","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T15:24:07Z","timestamp":1616513047000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Immunotherapy in treatment of leishmaniasis"],"prefix":"10.1016","volume":"233","author":[{"given":"Maryam","family":"Akbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Oryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Hatam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.imlet.2021.03.011_bib0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.exppara.2013.07.007","article-title":"Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro","volume":"135","author":"N\u00e9ris","year":"2013","journal-title":"Exp. Parasitol."},{"issue":"2","key":"10.1016\/j.imlet.2021.03.011_bib0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00436-019-06575-5","article-title":"Environmental and socioeconomic risk factors associated with visceral and cutaneous leishmaniasis: a systematic review","volume":"119","author":"Valero","year":"2020","journal-title":"Parasitol. Res."},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09712119.2008.9706946","article-title":"Morphologic changes due to cutaneous leishmaniosis in BALB\/c mice experimentally infected with Leishmania major","volume":"34","author":"Oryan","year":"2008","journal-title":"J. Appl. Anim. Res."},{"issue":"11","key":"10.1016\/j.imlet.2021.03.011_bib0020","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.imlet.2021.03.011_bib0025","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jinf.2014.07.016","article-title":"Leishmaniasis","volume":"69","author":"Pace","year":"2014","journal-title":"J. Infect."},{"key":"10.1016\/j.imlet.2021.03.011_bib0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.meegid.2013.07.021","article-title":"Genetic diversity of Leishmania major strains isolated from different clinical forms of cutaneous leishmaniasis in southern Iran based on minicircle kDNA, Infection","volume":"19","author":"Oryan","year":"2013","journal-title":"Genet. Evol."},{"issue":"5","key":"10.1016\/j.imlet.2021.03.011_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1179\/2047773213Y.0000000098","article-title":"Three Leishmania\/L. species\u2013L. infantum, L. major, L. Tropica\u2013as causative agents of mucosal leishmaniasis in Iran","volume":"107","author":"Shirian","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"10.1016\/j.imlet.2021.03.011_bib0040","first-page":"1","article-title":"Control of the leishmaniases","volume":"xii-xiii","year":"2010"},{"issue":"5","key":"10.1016\/j.imlet.2021.03.011_bib0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"issue":"3","key":"10.1016\/j.imlet.2021.03.011_bib0050","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000337450","article-title":"Molecular diagnosis and species identification of mucosal leishmaniasis in Iran and correlation with cytological findings","volume":"56","author":"Shirian","year":"2012","journal-title":"Acta Cytol."},{"issue":"3","key":"10.1016\/j.imlet.2021.03.011_bib0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.parint.2011.03.004","article-title":"In vitro antileishmanial activity and cytotoxicity of essential oil from Lippia sidoides Cham","volume":"60","author":"De Medeiros","year":"2011","journal-title":"Parasitol. Int."},{"issue":"2","key":"10.1016\/j.imlet.2021.03.011_bib0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5858\/arpa.2013-0098-OA","article-title":"Comparison of conventional, molecular, and immunohistochemical methods in diagnosis of typical and atypical cutaneous leishmaniasis","volume":"138","author":"Shirian","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0065","first-page":"1","article-title":"Plant-derived compounds in treatment of leishmaniasis","volume":"16","author":"Oryan","year":"2015","journal-title":"Iran. J. Vet. Res."},{"issue":"10","key":"10.1016\/j.imlet.2021.03.011_bib0070","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apjtm.2016.06.021","article-title":"Worldwide risk factors in leishmaniasis","volume":"9","author":"Oryan","year":"2016","journal-title":"Asian Pac. J. Trop. Med."},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00430-019-00640-7","article-title":"A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB\/c mice","volume":"209","author":"Vakili","year":"2020","journal-title":"Med. Microbiol. Immunol."},{"issue":"11","key":"10.1016\/j.imlet.2021.03.011_bib0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","article-title":"Leishmaniasis\u2013current chemotherapy and recent advances in the search for novel drugs","volume":"19","author":"Croft","year":"2003","journal-title":"Trends Parasitol."},{"issue":"2","key":"10.1016\/j.imlet.2021.03.011_bib0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clindermatol.2006.05.008","article-title":"Cutaneous leishmaniasis","volume":"25","author":"Bailey","year":"2007","journal-title":"Clin. Dermatol."},{"issue":"01","key":"10.1016\/j.imlet.2021.03.011_bib0090","first-page":"024","article-title":"Animal reservoirs for visceral leishmaniasis in densely populated urban areas","volume":"2","author":"Diniz","year":"2008","journal-title":"J. Infect. Dev. Countr."},{"issue":"04","key":"10.1016\/j.imlet.2021.03.011_bib0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3855\/jidc.4108","article-title":"Sexual and vertical transmission of visceral leishmaniasis","volume":"8","author":"Turchetti","year":"2014","journal-title":"J. Infect. Dev. Countr."},{"issue":"5","key":"10.1016\/j.imlet.2021.03.011_bib0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0035-9203(00)90055-5","article-title":"Visceral leishmaniasis control: a public health perspective","volume":"94","author":"Boelaert","year":"2000","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"8","key":"10.1016\/j.imlet.2021.03.011_bib0105","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1473-3099(02)00347-X","article-title":"Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda","volume":"2","author":"Guerin","year":"2002","journal-title":"Lancet Infect. Dis."},{"issue":"7385","key":"10.1016\/j.imlet.2021.03.011_bib0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/bmj.326.7385.377","article-title":"Leishmaniasis: new approaches to disease control","volume":"326","author":"Davies","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.imlet.2021.03.011_bib0115","first-page":"69","article-title":"Review of the current treatments for leishmaniases","volume":"3","author":"Lindoso","year":"2012","journal-title":"Res. Rep. Trop. Med."},{"issue":"5","key":"10.1016\/j.imlet.2021.03.011_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002871","article-title":"Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia","volume":"8","author":"Fern\u00e1ndez","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.imlet.2021.03.011_bib0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1874104501105010031","article-title":"Structures, targets and recent approaches in anti-leishmanial drug discovery and development","volume":"5","author":"Seifert","year":"2011","journal-title":"Open Med. Chem. J."},{"key":"10.1016\/j.imlet.2021.03.011_bib0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fmicb.2012.00283","article-title":"Conventional therapy and promising plant-derived compounds against trypanosomatid parasites","volume":"3","author":"Alviano","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.imlet.2021.03.011_bib0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.actatropica.2017.04.029","article-title":"Application of nanotechnology in treatment of leishmaniasis: a review","volume":"172","author":"Akbari","year":"2017","journal-title":"Acta Trop."},{"key":"10.1016\/j.imlet.2021.03.011_bib0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fimmu.2012.00099","article-title":"Vaccine development against Leishmania donovani","volume":"3","author":"Das","year":"2012","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.imlet.2021.03.011_bib0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001874","article-title":"Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis","volume":"6","author":"Singh","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"4","key":"10.1016\/j.imlet.2021.03.011_bib0150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S003118201600216X","article-title":"Leishmaniasis and various immunotherapeutic approaches","volume":"145","author":"Taslimi","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.imlet.2021.03.011_bib0155","doi-asserted-by":"crossref","first-page":"B244","DOI":"10.1016\/j.vaccine.2012.11.080","article-title":"Case study for a vaccine against leishmaniasis","volume":"31","author":"Alvar","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2021.03.011_bib0160","series-title":"Leishmaniases Reemerging Dis. Rij","first-page":"59","article-title":"Vaccines for human leishmaniasis: where do we stand and what is still missing","author":"Cec\u00edlio","year":"2018"},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-016-1553-y","article-title":"Possibilities and challenges for developing a successful vaccine for leishmaniasis","volume":"9","author":"Srivastava","year":"2016","journal-title":"Parasit. Vectors"},{"issue":"11","key":"10.1016\/j.imlet.2021.03.011_bib0170","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1517\/14712598.2014.945415","article-title":"Therapeutic vaccines for leishmaniasis","volume":"14","author":"Khamesipour","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"issue":"10","key":"10.1016\/j.imlet.2021.03.011_bib0175","first-page":"623","article-title":"Current status and perspectives of the immunotherapy of leishmaniasis","volume":"11","author":"El-On","year":"2009","journal-title":"Israel Med. Assoc. J. IMAJ"},{"issue":"6","key":"10.1016\/j.imlet.2021.03.011_bib0180","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00439-020-02130-w","article-title":"Human genetics of leishmania infections","volume":"139","author":"Blackwell","year":"2020","journal-title":"Hum. Genet."},{"key":"10.1016\/j.imlet.2021.03.011_bib0185","first-page":"155244","article-title":"Role of host genetics and cytokines in Leishmania infection","author":"Krayem","year":"2020","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1084\/jem.20052288","article-title":"Uptake of Leishmania major by dendritic cells is mediated by Fc\u03b3 receptors and facilitates acquisition of protective immunity","volume":"203","author":"Woelbing","year":"2006","journal-title":"J. Exp. Med."},{"issue":"5891","key":"10.1016\/j.imlet.2021.03.011_bib0195","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1126\/science.1159194","article-title":"In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies","volume":"321","author":"Peters","year":"2008","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.imlet.2021.03.011_bib0200","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.4049\/jimmunol.173.11.6521","article-title":"Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages","volume":"173","author":"van Zandbergen","year":"2004","journal-title":"J. Immunol."},{"issue":"5891","key":"10.1016\/j.imlet.2021.03.011_bib0205","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1126\/science.1162914","article-title":"Neutrophil soldiers or Trojan horses","volume":"321","author":"John","year":"2008","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.imlet.2021.03.011_bib0210","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2217\/imt.09.40","article-title":"Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature","volume":"1","author":"Okwor","year":"2009","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.imlet.2021.03.011_bib0215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/79734","article-title":"Dendritic cell regulation of Th 1-Th 2 development","volume":"1","author":"Moser","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imlet.2021.03.011_bib0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fcimb.2012.00069","article-title":"Natural killer cells in experimental and human leishmaniasis","volume":"2","author":"Bogdan","year":"2012","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3-4","key":"10.1016\/j.imlet.2021.03.011_bib0225","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.imbio.2007.12.005","article-title":"The innate immune response against Leishmania parasites","volume":"213","author":"Liese","year":"2008","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s004300100084","article-title":"Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice","volume":"190","author":"Mu\u00c8ller","year":"2001","journal-title":"Med. Microbiol. Immunol."},{"issue":"8","key":"10.1016\/j.imlet.2021.03.011_bib0235","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/microorganisms8081201","article-title":"Leishmania immunity: advancing immunotherapy and vaccine development","volume":"8","author":"Ikeogu","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.imlet.2021.03.011_bib0240","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2019.00670","article-title":"Cytokines: key determinants of resistance or disease progression in visceral leishmaniasis: opportunities for novel diagnostics and immunotherapy","volume":"10","author":"Dayakar","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.imlet.2021.03.011_bib0245","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.4049\/jimmunol.154.10.5320","article-title":"IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis","volume":"154","author":"Scharton-Kersten","year":"1995","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1074-7613(00)80460-4","article-title":"Type 1 interferon (IFN\u03b1\/\u03b2) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite","volume":"8","author":"Diefenbach","year":"1998","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.imlet.2021.03.011_bib0255","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/intimm\/3.6.587","article-title":"Establishment of resistance to Leishmania major infection in susceptible BALB\/c mice requires parasite-specific CD8+ T cells","volume":"3","author":"M\u00fcller","year":"1991","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0169-4758(98)01362-3","article-title":"How do protozoan parasites survive inside macrophages?","volume":"15","author":"Bogdan","year":"1999","journal-title":"Parasitol. Today"},{"issue":"2","key":"10.1016\/j.imlet.2021.03.011_bib0265","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7555\/JBR.27.20120064","article-title":"Development of Leishmania vaccines: predicting the future from past and present experience","volume":"27","author":"Mutiso","year":"2013","journal-title":"J. Biomed. Res."},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.det.2010.08.014","article-title":"Innate immunity and Leishmania vaccination strategies","volume":"29","author":"Birnbaum","year":"2011","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.imlet.2021.03.011_bib0275","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0065-2776(08)60912-8","article-title":"The host response to Leishmania infection","author":"Solbach","year":"1999"},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0280","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.iy.13.040195.001055","article-title":"The regulation of immunity to Leishmania major","volume":"13","author":"Reiner","year":"1995","journal-title":"Annu. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.imlet.2021.03.011_bib0285","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1348-0421.2007.tb03984.x","article-title":"Exposure to Leishmania major modulates the proportion of CD4T cells without affecting cellular immune responses","volume":"51","author":"Alimohammadian","year":"2007","journal-title":"Microbiol. Immunol."},{"issue":"4","key":"10.1016\/j.imlet.2021.03.011_bib0290","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/IAI.68.4.1760-1764.2000","article-title":"Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection","volume":"68","author":"Ajdary","year":"2000","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.imlet.2021.03.011_bib0295","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1128\/IAI.69.5.3232-3239.2001","article-title":"Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis","volume":"69","author":"Bottrel","year":"2001","journal-title":"Infect. Immun."},{"issue":"2","key":"10.1016\/j.imlet.2021.03.011_bib0300","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cyto.2013.12.016","article-title":"The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis","volume":"66","author":"Oliveira","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.imlet.2021.03.011_bib0305","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/152741","article-title":"Potential use of interleukin-10 blockade as a therapeutic strategy in human cutaneous leishmaniasis","volume":"2015","author":"Castellano","year":"2015","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-016-1807-8","article-title":"Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan","volume":"9","author":"Halliday","year":"2016","journal-title":"Parasit. Vectors"},{"issue":"12","key":"10.1016\/j.imlet.2021.03.011_bib0315","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1128\/IAI.70.12.6697-6706.2002","article-title":"Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB\/c mice","volume":"70","author":"Afrin","year":"2002","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.imlet.2021.03.011_bib0320","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1128\/IAI.71.6.3172-3182.2003","article-title":"Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection","volume":"71","author":"Colmenares","year":"2003","journal-title":"Infect. Immun."},{"issue":"11","key":"10.1016\/j.imlet.2021.03.011_bib0325","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1128\/IAI.69.11.6776-6784.2001","article-title":"Biochemical and biological characterization of the protective Leishmania pifanoi amastigote antigen P-8","volume":"69","author":"Colmenares","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.imlet.2021.03.011_bib0330","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2012.00128","article-title":"Protective immunity and vaccination against cutaneous leishmaniasis","volume":"3","author":"Okwor","year":"2012","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.imlet.2021.03.011_bib0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003300","article-title":"CD8+ T cells are preferentially activated during primary low dose Leishmania major infection but are completely dispensable during secondary anti-Leishmania immunity","volume":"8","author":"Okwor","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"9","key":"10.1016\/j.imlet.2021.03.011_bib0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004396","article-title":"MHC class II restricted innate-like double negative T cells contribute to optimal primary and secondary immunity to Leishmania major","volume":"10","author":"Mou","year":"2014","journal-title":"PLoS Pathog."},{"issue":"33","key":"10.1016\/j.imlet.2021.03.011_bib0345","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1016\/j.vaccine.2010.05.077","article-title":"Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge","volume":"28","author":"Okwor","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0350","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4049\/jimmunol.170.1.394","article-title":"CD4+ CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice","volume":"170","author":"Xu","year":"2003","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2021.03.011_bib0355","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12026-007-8012-y","article-title":"L-arginine metabolism and its impact on host immunity against Leishmania infection","volume":"41","author":"Wanasen","year":"2008","journal-title":"Immunol. Res."},{"issue":"3","key":"10.1016\/j.imlet.2021.03.011_bib0360","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/IAI.00611-07","article-title":"gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB\/c mice infected with Leishmania donovani","volume":"76","author":"Bhowmick","year":"2008","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.imlet.2021.03.011_bib0365","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/infdis\/jiq095","article-title":"Leishmania major attenuates host immunity by stimulating local indoleamine 2, 3-dioxygenase expression","volume":"203","author":"Makala","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.imlet.2021.03.011_bib0370","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jgar.2020.09.005","article-title":"Therapeutic effects of mesenchymal stem cells on cutaneous leishmaniasis lesions caused by Leishmania major","volume":"23","author":"Navard","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"10.1016\/j.imlet.2021.03.011_bib0375","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3389\/fimmu.2017.00893","article-title":"Effects of bone marrow mesenchymal stromal cell therapy in experimental cutaneous leishmaniasis in BALB\/c mice induced by Leishmania amazonensis","volume":"8","author":"Pereira","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.imlet.2021.03.011_bib0380","first-page":"197","article-title":"Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS","volume":"12","author":"Mastroianni","year":"2004","journal-title":"Infez. Med."},{"key":"10.1016\/j.imlet.2021.03.011_bib0385","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijbiomac.2015.04.043","article-title":"Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response","volume":"79","author":"Chaurasia","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"issue":"17","key":"10.1016\/j.imlet.2021.03.011_bib0390","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1111\/bph.12754","article-title":"Coating doxorubicin\u2010loaded nanocapsules with alginate enhances therapeutic efficacy against L eishmania in hamsters by inducing T h1\u2010type immune responses","volume":"171","author":"Kansal","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.imlet.2021.03.011_bib0395","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1128\/IAI.01527-07","article-title":"Immunization with a Toll-like receptor 7 and\/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB\/c mice","volume":"76","author":"Zhang","year":"2008","journal-title":"Infect. Immun."},{"key":"10.1016\/j.imlet.2021.03.011_bib0400","first-page":"100048","article-title":"Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in L. infantum-infected dogs","volume":"4","author":"Nascimento","year":"2020","journal-title":"Vaccine: X"},{"issue":"12","key":"10.1016\/j.imlet.2021.03.011_bib0405","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.vaccine.2005.11.011","article-title":"Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis","volume":"24","author":"Rafati","year":"2006","journal-title":"Vaccine"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247821000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247821000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:38:54Z","timestamp":1759045134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247821000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":81,"alternative-id":["S0165247821000493"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2021.03.011","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in treatment of leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2021.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}